| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.31 [0.93, 1.85] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.21 [0.93, 1.57] | | < 1 | | 0% | 1 study (1/-) | 7.7 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.95 [0.66, 1.36] | | > 1 | | 0% | 1 study (1/-) | 38.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.67 [0.11, 4.05] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.54 [1.02, 2.33] | | < 1 | | 0% | 1 study (1/-) | 2.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.19 [0.87, 1.64] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.67 [0.19, 2.40] | | < 1 | | 0% | 1 study (1/-) | 73.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.38 [0.97, 1.97] | | < 1 | | 0% | 1 study (1/-) | 3.7 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.98 [0.18, 21.97] | | < 1 | | 0% | 1 study (1/-) | 29.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.76] | | < 1 | | 0% | 1 study (1/-) | 65.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.24 [0.48, 3.19] | | < 1 | | 0% | 1 study (1/-) | 32.6 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.49 [0.02, 14.76] | | < 1 | | 0% | 1 study (1/-) | 65.6 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.91 [0.58, 1.43] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.50 [0.61, 3.72] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.39 [0.44, 4.43] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.25 [0.01, 5.48] | | < 1 | | 0% | 1 study (1/-) | 80.9 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.36 [0.71, 2.60] | | < 1 | | 0% | 1 study (1/-) | 17.5 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.99 [0.14, 7.06] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.25 [0.01, 5.48] | | < 1 | | 0% | 1 study (1/-) | 80.9 % | NA | not evaluable | | non important | - |
| Dysphonia TRAE (grade 3-4) | 0.99 [0.02, 49.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.16 [0.53, 2.54] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.76 [0.28, 2.08] | | < 1 | | 0% | 1 study (1/-) | 70.1 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.99 [0.36, 10.93] | | < 1 | | 0% | 1 study (1/-) | 21.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.98 [0.18, 21.97] | | < 1 | | 0% | 1 study (1/-) | 29.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.02, 49.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.98 [0.18, 21.97] | | < 1 | | 0% | 1 study (1/-) | 29.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 7.04 [0.86, 57.54] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 5.00 [0.58, 43.02] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.97 [0.18, 88.38] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.04 [0.55, 1.96] | | < 1 | | 0% | 1 study (1/-) | 45.1 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 1.11 [0.72, 1.72] | | < 1 | | 0% | 1 study (1/-) | 31.2 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.30 [0.68, 2.49] | | < 1 | | 0% | 1 study (1/-) | 21.6 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.10 [0.73, 1.66] | | < 1 | | 0% | 1 study (1/-) | 32.4 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.25 [0.01, 5.48] | | < 1 | | 0% | 1 study (1/-) | 80.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.49 [0.02, 14.76] | | < 1 | | 0% | 1 study (1/-) | 65.6 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.76 [0.28, 2.08] | | < 1 | | 0% | 1 study (1/-) | 70.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 10.01 [0.55, 184.02] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.49 [0.04, 5.46] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.49 [0.04, 5.46] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.99 [0.56, 1.74] | | < 1 | | 0% | 1 study (1/-) | 51.7 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 9.31 [3.63, 23.82] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Urticaria TRAE (grade 3-4) | 1.98 [0.07, 59.21] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.88 [0.46, 1.70] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.66 [0.34, 1.29] | | < 1 | | 0% | 1 study (1/-) | 88.7 % | NA | not evaluable | | non important | - |
